ArticleHIV medicine2026
Achieving reimbursable PrEP is insufficient to increase and diversify the users attending community-based services.
Article in HIV medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesThe reimbursement of HIV pre-exposure prophylaxis (PrEP) in Italy was expected to increase uptake and diversify users. We assessed changes in PrEP initiation patterns before and after reimbursement at a community-based service.
methodsWe conducted a monocentric retrospective cohort study that included all individuals who initiated PrEP between September 2017 and October 2024. Participants were stratified according to PrEP initiation before and after June 2023, when reimbursed PrEP was made available. Monthly PrEP initiations were analysed using single-group interrupted time series analysis (ITSA) with segmented linear regression, including two intervention points (July 2020 and June 2023) and accounting for autocorrelation.
resultsWe included 1394 individuals who initiated PrEP: 1019 (73.1%) before and 375 (26.9%) after June 2023. Participants were predominantly cisgender men (96.7%), gay, bisexual and other men who have sex with men (GBMSM) (95.1%) and white (82.1%). After reimbursement, modest differences were observed, including a higher proportion of white individuals (84.0% vs. 81.5%) and fewer lifetime sexual partners (≥30 partners: 73.7% vs. 81.0%), while discontinuation rates remained similar. ITSA showed a marked immediate increase in PrEP initiations after the COVID-19 lockdown (+12.7/month; 95% CI 9.3, 16.1), followed by a flat trend thereafter. PrEP reimbursement was not associated with a significant immediate increase (+4.7/month; 95% CI -1.5, 10.9) and was followed by a negative change in the trend (-0.54/month; 95% CI -0.92, -0.15).
conclusionsIn this community-based setting, reimbursed PrEP was not associated with a substantial increase in uptake or diversification of users, suggesting that additional implementation strategies beyond drug reimbursement may be required to improve equitable access.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.